Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies

Human serum IgG contains multiple glycoforms which exhibit a range of binding properties to effector molecules such as cellular Fc receptors. Emerging knowledge of how the Fc glycans contribute to the antibody structure and effector functions has opened new avenues for the exploitation of defined an...

Full description

Saved in:
Bibliographic Details
Published inBiochimica et biophysica acta Vol. 1860; no. 8; pp. 1655 - 1668
Main Authors Le, Ngoc Phuong Lan, Bowden, Thomas A., Struwe, Weston B., Crispin, Max
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2016
Elsevier Pub. Co
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human serum IgG contains multiple glycoforms which exhibit a range of binding properties to effector molecules such as cellular Fc receptors. Emerging knowledge of how the Fc glycans contribute to the antibody structure and effector functions has opened new avenues for the exploitation of defined antibody glycoforms in the treatment of diseases. Here, we review the structure and activity of antibody glycoforms and highlight developments in antibody glycoengineering by both the manipulation of the cellular glycosylation machinery and by chemoenzymatic synthesis. We discuss wide ranging applications of antibody glycoengineering in the treatment of cancer, autoimmunity and inflammation. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc. •IgG glycosylation impacts antibody effector function.•Modulation of antibody glycosylation has therapeutic potential.•Antibody glycoforms exhibit anti- and pro-inflammatory properties.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0304-4165
0006-3002
1872-8006
DOI:10.1016/j.bbagen.2016.04.016